President Donald Trump signed an executive order imposing 100% tariffs on imported brand-name drugs, citing U.S. reliance on imports as the rationale and positioning the action under Section 232 for national security purposes. The order includes multiple carveouts, including exemptions tied to manufacturing commitments and agreements with the administration. The tariff structure varies by origin and company behavior: some manufacturers that build U.S. facilities face a reduced 20% rate, while drugs from certain trade-agreement partners face a lower or unspecified rate. Additional exemptions cover generics, orphan drugs, and brand-name products from firms that enter Most Favored Nation (MFN) agreements. PhRMA and other industry groups criticized the move, warning that higher costs could undermine investments and jeopardize manufacturing plans. In parallel, reporting indicates the White House is negotiating new confidential pricing deals with smaller drugmakers to reduce tariff exposure. For biotech and pharma, the key issue is whether tariff risk will be managed through domestic production commitments, MFN-style pricing agreements, or revised launch and supply strategies—factors that can directly affect near-term pipeline commercialization timelines and access.